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Amyloid-beta (Aβ) peptide oligomers are believed to be the causative agents of
Alzheimer’s disease (AD). Though post-mortem examination shows that insoluble fibrils
are deposited in the brains of AD patients in the form of intracellular (tangles) and
extracellular (plaques) deposits, it has been observed that cognitive impairment is linked
to synaptic dysfunction in the stages of the illness well before the appearance of these
mature deposits. Increasing evidence suggests that the most toxic forms of Aβ are
soluble low-oligomer ligands whose amounts better correlate with the extent of cognitive
loss in patients than the amounts of fibrillar insoluble forms. Therefore, these ligands hold
the key to a better understanding of AD prompting the search for clearer correlations
between their structure and toxicity. The importance of such correlations and their
diagnostic value for the early diagnosis of AD is discussed here with a particular emphasis
on the transient nature and structural plasticity of misfolded Aβ oligomers.
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Protein Conformational Disorders
Cerebral proteopathies including Alzheimer’s, Parkinson’s, and Huntington’s diseases result from
progressive amyloidogenesis for which protein misfolding is the cause (Eisenberg and Jucker,
2012).The complexity of these diseases is the main reason behind the persistent lack of efficient
therapeutic approaches. Traditional drug development relies on finding a therapeutic target which
for most diseases can be traced down to an individual molecule, mutation or infection. In contrast,
proteopathies are process disorders which develop over many years through a chain of conforma-
tional changes starting with an abnormally folded protein or/as in prion diseases, as a result of
permissive templating of an endogenous protein by an exogenous amyloidogenic form. Therefore,
proteopathies are often referred to as protein conformational disorders with a particular empha-
sis on a specific causative agent.This mini-review focuses on one of such agents—amyloid-beta or
Aβ—and discusses the elusive nature of its development into cytotoxic oligomers (Meli et al., 2014).
Aβ stands for a proteolytic product of a transmembrane amyloid precursor protein (APP).
This is a 40–42 residue peptide which constitutes a primary structural component of insol-
uble fibrils accumulating in microscopic deposits, senile plaques, that are found in the post-
mortem brains of Alzheimer’s disease (AD) patients (Glenner and Wong, 1984; Masters et al.,
1985). Early studies showed that in such plaques Aβ existed in a stable multimeric form and
some credence was given to the role of Aβ in the disease by the demonstration that aggre-
gated forms of Aβ were toxic to neuronal cells in vitro and in vivo (Walsh and Selkoe, 2007),
Abbreviations: AD, Alzheimer’s disease; APP, amyloid precursor protein; ADDLs, amyloid-derived diffusible ligands; TTR,
transthyretin; SDS, sodium dodecyl sulphate.
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whereas monomeric, soluble forms were innocuous. However, no
correlation was found between the number of amyloid plaques
in brain and the extent of cognition loss in examined brains of
AD patients. Instead, better correlations were apparent between
(i) the total amount of soluble and insoluble β-amyloid in brain
and cognitive decline (McLean et al., 1999) and (ii) the amounts
of Aβ oligomers and the extent of cognitive loss in patients as
opposed to the number of fibrils (Glabe, 2008).These findings are
in a striking agreement with that fibrils are less toxic to neurons
than soluble oligomers (Sakono and Zako, 2010) and that lower-
ing the cytotoxicity of β-amyloid does not necessarily reduce fiber
formation (Zerovnik et al., 2011; Jiang et al., 2013). Therefore, Aβ
fibrils can be viewed as repositories of soluble intermediates that
are in equilibrium with insoluble forms (Bieschke et al., 2012)
(Figure 1).
Outstanding questions relate to the precise relationships
between the primary and secondary structure of Aβ and those
tertiary interactions that underpin different polymorphic forms,
transient or equilibrated, but which remain elusive tomost exper-
imental conditions that fail to adequately replicate Aβ aggrega-
tion pathways (Bitan et al., 2005; Philo, 2006). Yet again, it is
becoming apparent that it is the conformational plasticity of Aβ
which is responsible for the observed polymorphism and toxi-
city (Hubin et al., 2014). Along the same lines, it is reasonable
to consider a sequence of nucleating processes each of which
may potentially lead to different cytotoxicity (Necula et al., 2007;
Miller et al., 2010). Such a notion prompts an important conclu-
sion that key factors for the cytotoxic effects of β-amyloid may be
confined to interactions between soluble oligomers and cellular
FIGURE 1 | Schematic representations of (A) spontaneous Aβ
aggregation from β-sheet–nucleating monomers (lag) phase to
β-sheet-rich oligomers, protofibrils and fibrils (PDB entries 1BEG,
2LFM, 2GSP, and 2OTK). Fibril model is reproduced under the terms
of the creative Commons Attribution non-commercial license from
Marshall (2009). (B) Two elementary units, β-hairpin and β-arch, leading
to different assembly pathways (PDB entries 2OTK and 2LNQ rendered
by Swiss PDB Viewer).
membranes (Broersen et al., 2010), (Broersen et al., 2010; Stefani,
2012) favoring stronger binders (Miller et al., 2010).
Aβ Oligomerisation: Conformation, Size
and Elementary Units
In fibrils Aβ is arranged into a parallel, in-register cross-beta
architecture in which individual β-sheets run perpendicular to
the fibril axis. A β-turn-β arc, which in contrast to a β-hairpin
is side-chain-bonded, is reported as an elementary unit for both
fibrils and nucleators (Kajava et al., 2010) but remains unrecog-
nized as a dominant conformation for oligomers. Largely this is
due to the more pronounced conformational plasticity of Aβ in
low oligomeric structures which are prone to specific changes in
response to environmental factors (Miller et al., 2010).
Encouragingly, such a permissive conformational background
as well as polymorphic plasticity allow for the development
of conformation-dependent oligomer-specific antibodies. For
example, OC polyclonal antibodies recognize fibrils or fibril-
lar oligomers but not pre-fibrillar oligomers which though have
broadly the same sizes are immunologically different and are rec-
ognized by A11 antibodies (Kayed et al., 2003, 2007). Fibrils and
pre-fibrillar oligomers therefore have different conformation-
dependent epitopes which suggests that oligomer conforma-
tions are likely to be main determinants of cytotoxicity (Ladi-
wala et al., 2012). Although pre-fibrillar oligomers can vary
in size and morphology (Benilova et al., 2012) their variety is
dependent on experimental conditions used (Lee et al., 2007;
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Gillam and MacPhee, 2013). The size alone thus cannot serve as
a reliable indicator of oligomer conformation or toxicity. Sim-
ilarly, the morphology of soluble aggregates, which tends to be
dominated by spheroidal forms (Lambert et al., 1998), seem to
bear little relevance to size-dependent toxicity. Low oligomers,
often termed amyloid-derived diffusible ligands (ADDLs), are
believed to range in diameter from 1 to 15 nm (Hoshi et al.,
2003), with similar morphologies expressed at the micrometer
scale (Westlind-Danielsson andArnerup, 2001). β-hairpins stabi-
lized into U-shape conformations are maintained in these struc-
tures. Deviations in in-register β-sheet arrangements occur with
increasing size when the assembly is forced to adopt a twist which
destabilizes further fibril-like growth thus limiting the assem-
bly to lower oligomers. In contrast, twist pairs as small as Aβ
pentamers can be stabilized through a hydrophobic interface to
seed conformational templates for fibrillogenesis (Kahler et al.,
2013).
However, any assignment of a specific conformation is ham-
pered by the heterogeneity and instability of lower oligomers, and
consequently questions the existence of a specific toxic oligomer
(Hubin et al., 2014). Analysing the dynamics of the conforma-
tional space available to Aβ may provide better insights. For
example, proteolytic cleavage of SDS-stable globule-like aggre-
gates helped to reveal a C-terminal part of Aβ sequence buried
in the hydrophobic core suggesting conformational adaptability
of a solvent-exposed N-terminal fragment (Barghorn et al., 2005).
Proposed as intermediates toward fibril formation (Chimon and
Ishii, 2005) these structures were found to be toxic pre-fibrillar
oligomers (A11-positive) suggesting that the supramolecular
packing of a similar elementary β-sheet unit is different from that
in fibrils (Chimon et al., 2007). In pre-fibrillar oligomers the unit
was found to be an anti-parallel β-sheet followed by an in-register,
parallel intermolecular sheet (Olejniczak et al., 2008; Yu et al.,
2009). With the dimer covalently locked through an introduced
disulphide bond, the oligomers could still be recognized by the
same antibody suggesting constraint-independent binding (Yu
et al., 2009). More recent evidence broadens potential pathways
to toxic oligomers with mechanisms involving out-of-register β-
sheets (Liu et al., 2012) and staggered anti-parallel arrangements
(Tay et al., 2013).
In this light, revealing an elementary monomeric conforma-
tion appears to be timely and appealing. In an exemplary attempt,
an Aβmonomer covalently locked into a stabilized β-hairpin was
shown to associate into oligomeric and pre-fibrillar structures
but not mature fibrils, while, remarkably, exhibiting cytotoxic-
ity and antibody recognition typical of native oligomers (Sand-
berg et al., 2010; Dubnovitsky et al., 2013). These results confirm
that Aβ peptide (primary structure) folded into a hairpin (sec-
ondary structure) constitutes the elementary monomeric motif
supporting the formation of oligomers.
However, links between the elementary units and their ter-
tiary arrangements in oligomers are far less clear. Some evi-
dence points in favor of oligomeric intermediates having specific
structural topologies, e.g., assembled β–barrels, which are A11-
positive. Given that the binding of A11 is sequence-independent
and that it recognizes other non-amyloid oligomers including α-
haemolysin and heat shock proteins (Yoshiike et al., 2008), these
proposed topologies are likely to be off-pathway intermediates.
For the same reason, the structures could represent oligomeric
forms adopted by other amyloid-forming peptides, and can be
used as β-sheet amyloid mimetics.
Uncertainties in providing explicit relationships between sec-
ondary and tertiary structures in transient oligomers encour-
age alternative representations of monomeric units. One of such
alternatives is an atypical secondary structure motif—an α-sheet.
Similar to β-sheets this structure forms pleated structures which
however differ by that all peptide-bond carbonyls lie in the same
direction on one side of the pleat while all amino groups mirror
the arrangement on the opposite side of the pleat. This enables
opposite charges on the opposite edges of one pleat, also referred
to as a polar pleated sheet, and more pronounced sheet flat-
tening (Pauling and Corey, 1951; Armen et al., 2004). Peptides
designed to adopt this secondary structure were able to bind
toxic oligomers of two unrelated amyloid proteins, Aβ (1-42) and
transthyretin (TTR) (Armen et al., 2004; Hopping et al., 2014).
The structure is also considered as promising for addressing the
main paradox of structure-activity relationships in amyloidoge-
nesis by delineating the dependence of the process on peptide
sequences from that it is mainly driven by backbone stabilization
factors.
Yet, this and any other alternative structures can only pro-
vide indirect evidence which would require validation for native
amyloidogenic sequences.
Aβ Oligomers: Toxicity and Synaptic
Degeneration
AD is the most common form of dementia which affects episodic
memory. Plasticity of the synapse would appear to be intimately
involved (Martin et al., 2000), whereas the structure of the synap-
tic network changes in response to external or internal stimuli
enabling at a later date the repeated access to those stimuli. Thus,
the most damaged facet of memory in AD is the loss of seman-
tic memory, the store of factual and conceptual knowledge that is
not linked to a specific memory.
Changing the strength of synaptic connections between neu-
rons is widely thought to be the mechanism by which memory
traces are encoded and stored in the brain. This hypothesis states
that activity dependant synaptic plasticity is induced at appro-
priate synapses during memory formation and is necessary and
sufficient for the information storage underlying memory. An
exemplary insight into how Aβ production and aggregation may
give rise to memory loss in vivo (Kayed and Lasagna-Reeves,
2013) can be demonstrated by a recent finding (Russell et al.,
2012).
Specifically, Aβ oligomers blocked long-term potentiation
(LTP) in the hippocampal slices of fetal rats. LTP is an exper-
imental paradigm of synaptic plasticity, which is characterized
by an increasing response with repeated stimulation over time.
Aβ oligomers at nanomolar levels derived by incubation of syn-
thetic Aβ, or isolation from cellular supernatants, blocked main-
tenance but not initiation of LTP. Blockage was alleviated by the
additional presence of protecting antibody or the application of
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FIGURE 2 | Conceptual schematic of the nanoprobe-based capture of
Aβ oligomers. A capturing bait conjugated to a gold nanoparticle (yellow)
discriminates an Aβ oligomer in β-sheet conformation (green) from unfolded
or folded monomers (blue and red) (PDB entries 1BEG, 2LFM, 2GSP, and
2OTK).(Georganopoulou et al., 2005; Chikae et al., 2008; Santos et al.,
2008; Herskovits et al., 2013).
scrambled Aβ (Walsh et al., 2002). There is plenty of direct exper-
imental evidence to support the notion of toxic oligomers (Walsh
et al., 2002; Kayed et al., 2003, 2007; Haass and Selkoe, 2007;
Tomic et al., 2009; Mucke and Selkoe, 2012; Lesne et al., 2013),
also suggesting that the activity of causing dementia may occur
across a broad oligomer range. For example, Aβ dodecamers
were identified in human brain extracts and found to bind cul-
tured neurons in a manner similar to synthetic ADDLs (Lacor
et al., 2004). The implication of these brain-derived dodecamers
as pathophysiologically relevant Aβ oligomers is supported by the
isolation of a similar 56 kDa oligomer from APP-overexpressing
AD transgenic mice that was capable of disrupting memory upon
injection into young wild type rats (Lesne et al., 2006) At the
lower end of the oligomer spectrum a particular neurotoxic effect
is assigned to dimers and trimers (Hung et al., 2008; Ono et al.,
2009), which were also found to inhibit LTP in hippocampal slices
(Shankar et al., 2007, 2008).
Amyloid oligomers block LTP in hippocampal neurones by
binding and cross-linking receptors that are then internalized
and degraded in the post-synaptic neuron. Drastic neuronal
damage also occurs. Loss of neuronal density and synapse con-
centration is a marked characteristic of a post-mortem AD
brain, and cognition loss can occur when levels of soluble
oligomers are high, many months before the appearance of senile
plaques (Moechars et al., 1999). Low concentrations (pM) of
β-amyloid, commensurate with levels found in normal human
brain, produced a marked increase in LTP in hippocampal
slices (Puzzo et al., 2008), whereas larger concentrations (nM)
led to a block raising the possibility that the normal function
of Aβ may be to modulate synaptic plasticity positively. This
finding raises the problem that any therapeutic reduction in
Aβ may have to leave trace amounts of Aβ to function dur-
ing normal development. Indeed, soluble oligomeric forms in
aqueous extracts of post-mortem brains from patients showing
early cognitive loss contained SDS-stable oligomers suggesting
their early accumulation in the disease process (McLean et al.,
1999).
Direct implications of these and other findings is the necessity
of diagnostic detection platforms that would be able to capture
and detect circulating trace amounts of Aβ oligomers (Figure 2).
Final Remarks on the Diagnostic Value of
Aβ
Despite the need and urgency and that all experimental evidence
points to the substantial value of Aβ oligomers for early diagnosis
and as a possible surrogate biomarker in clinical trials (Sian et al.,
2000; Austen et al., 2008; Gao et al., 2010; Yam et al., 2011; Her-
skovits et al., 2013; Lesne et al., 2013), Aβ has yet to be validated as
a clinically acceptedmarker for AD (Hampel et al., 2010; Humpel,
2011; Chintamaneni and Bhaskar, 2012; Rosen et al., 2013).
Admittedly, the lack of progress in this area is due to the out-
lined uncertainties of amyloid formation, which compromise the
very notion of efficient diagnosis as a synergistic balance between
specificity and the speed of obtaining results. However, given that
the post-mortem analysis of ex-vivo brain specimens remains the
only definitive AD diagnosis any test able to differentiate soluble
oligomers at an early pre-fibrillar stage is of significant value and
must be tried.
The development of technologies based on conformation-
responsive detection of Aβ is arguably the most appealing
approach toward this. The diagnostic value of such a strategy
is based on direct correlations between oligomer amounts and
disease progression, but yet again stumbles upon our poor under-
standing of precise conformational states that are responsible
for AD. Revealing these conformations, transient or stable, may
underpin the development of new molecular modalities with dif-
ferentially selective and high affinity profiles to soluble oligomers
that can be used as molecular sensors or baits enabling the
capture of amyloid precursors in biological matrices.
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